Work

FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.2559

Authors: Lee S. Rosen, D. Ross Camidge, Danny Khalil, Thomas Lillie, Jo Carter, David Krige, Jessica Davies, David Miles, Minesh Patel, Vladimir Evilevitch, Isabel Prieto González-Albo, Brian Champion, Aung Naing

Institutions: University of California, Los Angeles, University of Colorado Cancer Center, Memorial Sloan Kettering Cancer Center, PsiOxus Therapeutics (United Kingdom), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286295647

Cites:

Cited by: 2

Related to: 10